Menu

Nobel-Winning Biochemist Paul Boyer Dies

The UCLA researcher was lauded for figuring out how ATP synthase works.

Jun 7, 2018
Shawna Williams

UCLAPaul Boyer, a biochemist known for deducing how the vital cellular fuel ATP gets made, died of respiratory failure on June 2. He was 99 years old.

“Paul Boyer inspired both trust and ambition in his fellow faculty members, and had perhaps the most positive character of anyone most of us have ever known,” his friend and colleague David Eisenberg of the University of California, Los Angeles, says in a statement. “He combined true modesty with unstoppable persistence and unmatched personal interactions.”

Boyer grew up in Provo, Utah. His mother died of Addison’s disease when he was 15. He would later write in an autobiography for the Nobel, “Discoveries about the adrenal hormones, that could have saved her life, came too late. Her death contributed to my later interest in studying biochemistry. . .” He attended Brigham Young University, then did his graduate work in biochemistry at the University of Wisconsin. After a postdoc at Stanford University, he started his own lab at the University of Minnesota, where he investigated the mechanisms of enzymes.

Boyer left the University of Minnesota for UCLA in 1963, when he served as the founding director of its Molecular Biology Institute. In the 1970s, he put forward a model in which the subunits of the enzyme ATP synthase work together like a rotor and shaft, powered by a hydrogen ion gradient, to produce ATP, a molecule that fuels myriad cellular processes. John Walker of Cambridge University confirmed the structure using X-ray crystallography in the early 1990s, and in 1997, Boyer and Walker were awarded the Nobel Prize in Chemistry along with Jens Skou, who died in late May.

According to the Washington Post, Boyer is survived by his wife Lyda, two daughters, eight grandchildren, and six great-grandchildren. His son died in 2001.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.